---
title: "Why Is Psyence Biomedical Stock Trading Lower On Tuesday?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283538970.md"
description: "Psyence Biomedical Ltd (NASDAQ:PBM) shares fell over 12% on Tuesday after a significant rally of nearly 72.63% on Monday, driven by President Trump's executive order to expedite mental illness treatments and a $50 million commitment for ibogaine research. Investors are taking profits following the surge. Despite the recent gains, the stock remains 43.93% down over the past year, trading at $10.90 in premarket, with key resistance at $12.50 and support at $10."
datetime: "2026-04-21T16:54:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283538970.md)
  - [en](https://longbridge.com/en/news/283538970.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283538970.md)
---

# Why Is Psyence Biomedical Stock Trading Lower On Tuesday?

**Psyence Biomedical Ltd** (NASDAQ:PBM) shares are trading lower on Tuesday by more than 12%, a sharp reversal after a massive rally on Monday. Investors appear to be engaging in profit-taking after the stock’s recent vertical climb.

The stock surged nearly 72.63% during Monday’s regular trading hours. At the time, the psychedelic sector received a major boost.

President **Donald Trump** signed an executive order to accelerate mental illness treatments. This order specifically targets faster reviews for psychedelic drugs. It also includes a reported $50 million commitment for ibogaine research.

## Ibogaine Supply Chain Advantages

Psyence Biomedical stands out due to its GMP-compliant ibogaine platform. Through PsyLabs, the company manages sourcing, extraction, and purification in Africa. Psyence is pitching itself as a rare picks-and-shovels supplier. The company already holds stabilized, pharmaceutical-grade ibogaine doses in its current inventory.

## Psyence Technical Analysis

PBM is rebounding from its February low but remains well below its 52-week high. The stock is trading 224.7% above its 20-day simple moving average (SMA) and 130.7% above its 100-day SMA.

The relative strength index (RSI), a momentum gauge, is 96.18.

On a longer lens, the stock is down 43.93% over the past 12 months, which keeps the bigger-picture tape fragile despite the recent surge.

-   **Key Resistance**: $12.50
-   **Key Support**: $10

**PBM Stock Price Activity:** Psyence Biomedical shares were down 3.54% at $10.90 during premarket trading on Tuesday, according to Benzinga Pro data.

_Photo Courtesy: solarseven on Shutterstock.com_

### Related Stocks

- [PBM.US](https://longbridge.com/en/quote/PBM.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBMWW.US](https://longbridge.com/en/quote/PBMWW.US.md)

## Related News & Research

- [Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing | PBM Stock News](https://longbridge.com/en/news/286572370.md)
- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)
- [Enanta Pharma's RSV Bet And Immunology Ambitions](https://longbridge.com/en/news/286895623.md)
- [Engage Bio Acquired by Lilly to Accelerate Development of Non-Viral Genetic Medicines](https://longbridge.com/en/news/287077005.md)
- [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md)